Zevra Therapeutics (ZVRA) Operating Expenses (2014 - 2026)

Zevra Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $25.2 million for Q1 2026.

• Quarterly Operating Expenses rose 10.4% year-over-year to $25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.7 million (down 4.95% YoY) and the FY2025 annual result came in at $90.4 million, down 6.81% from the prior year.
• Operating Expenses was $25.2 million for Q1 2026 at Zevra Therapeutics, up from $23.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $27.2 million in Q3 2024 and bottomed at $5.8 million in Q1 2022.
• A 5-year average of $20.0 million and a median of $22.8 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 323.65% — and 2023, when it plunged 46.12%.
• Zevra Therapeutics' Operating Expenses stood at $11.3 million in 2022, then jumped by 130.07% to $26.1 million in 2023, then fell by 6.14% to $24.5 million in 2024, then declined by 6.14% to $23.0 million in 2025, then grew by 9.58% to $25.2 million in 2026.
• Business Quant data shows ZVRA's Operating Expenses at $25.2 million in Q1 2026, $23.0 million in Q4 2025, and $20.4 million in Q3 2025.